To Toucan:
The more intriguing question is why did the company voluntarily delist, knowing that to do so would immediately wreck the PPS (and its market cap), and trigger a default on the convertible notes? Any CFO worth its salt could have delayed/appealed a delist notice for another month or two.
Why willingly shoot yourself in the chest when your PPS is trading at $1.90? It just doesn't make sense ... unless, of course, you had "other" plans.
The more intriguing question is why did the company voluntarily delist, knowing that to do so would immediately wreck the PPS (and its market cap), and trigger a default on the convertible notes? Any CFO worth its salt could have delayed/appealed a delist notice for another month or two.
Why willingly shoot yourself in the chest when your PPS is trading at $1.90? It just doesn't make sense ... unless, of course, you had "other" plans.
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
